<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05124574</url>
  </required_header>
  <id_info>
    <org_study_id>IRBN1362021</org_study_id>
    <nct_id>NCT05124574</nct_id>
  </id_info>
  <brief_title>Transplacental Transmission of Severe Acute Respiratory Syndrome(SARS-COV-2) Study</brief_title>
  <official_title>Prospective Evaluation of Transplacental Transmission of SARS-COV-2 in a Cohort of 10 Mother/Child Dyads</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      SARS-CoV-2, the agent responsible for pandemic SARS-COV-2 infection, is transmitted mainly by&#xD;
      respiratory droplets. Regarding maternal-fetal transmission, even if the mode of transmission&#xD;
      from mother to fetus is not clear, some cases of perinatal transmission have been described,&#xD;
      but without certainty on the routes of placental contamination, trans-cervical or by&#xD;
      environmental exposure. .&#xD;
&#xD;
      The case described by J. Vivanti of a newborn with neonatal neurological involvement and&#xD;
      whose mother had been infected during the last trimester of pregnancy reports possible&#xD;
      transplacental transmission in a context of positive and elevated viremia in the mother and&#xD;
      positive viremia in the newborn.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In 2021, it becomes essential to clarify if and how SARS-COV-2 reaches the fetus, in order to&#xD;
      prevent neonatal infection, optimize pregnancy management and better understand the&#xD;
      pathogenesis of SARS-COV-2.&#xD;
&#xD;
      SARS-COV-2, ACE2 and TMPRSS2 co-receptors are highly expressed in placental tissues and may&#xD;
      be actively involved in transplacental transmission of the virus. From a case of&#xD;
      materno-fetal transmission described by our team (publication in progress), we observed&#xD;
      placental expression of the Spike SARS-COV-2 protein, but also of the ACE2 receptors, TMPRSS2&#xD;
      and cathepsin L. Cytotrophoblast and syncytiotrophoblast cell stains were positive within the&#xD;
      placental villi. Maternal leukocytes were also labeled for these proteins.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Spike SARS-COV-2 protein in placental tissues</measure>
    <time_frame>Baseline : childbirth</time_frame>
    <description>expression of the Spike SARS-COV-2 protein in placental tissues</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACE2 receptors in placental tissues</measure>
    <time_frame>Baseline : childbirth</time_frame>
    <description>expression of the ACE2 receptors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TMPRSS2 in placental tissues</measure>
    <time_frame>Baseline : childbirth</time_frame>
    <description>expression of the TMPRSS2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cathepsin L in placental tissues</measure>
    <time_frame>Baseline : childbirth</time_frame>
    <description>expression of the cathepsin L</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>SARS-COV-2 Infection</condition>
  <arm_group>
    <arm_group_label>mothers infected with SARS-COV-2 at the time of delivery.</arm_group_label>
    <description>Maternal-fetal transmission of SARS-COV-2 is likely and may require co-expression of the virus receptor (ACE2) and at least one activator of virus internalization (TMPRSS2 and/or cathepsin) in a cell to make it susceptible to SARS-COV-2 infection.&#xD;
To confirm these hypotheses, it is necessary to explore these mechanisms of fetal transmission in a larger number of mothers infected with SARS -CoV-2 at the time of delivery.&#xD;
Informed information will be given in the delivery room, initially orally by the midwives, to any mother presenting with an SARS-COV-2 infection (symptomatic or not) (whatever the variant involved). An information leaflet will also be given to the patient and consent will be systematically obtained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples concern SARS-COV-2 + pregnant women at the time of childbirth</intervention_name>
    <description>nasopharyngeal PCR in the mother (performed systematically in this epidemic context),&#xD;
Blood samples: 1 EthyleneDiamineTetraacetic Acid (EDTA) tube (immunohistochemistry), 1 yellow tube (COVID + RT-qPCR serology).&#xD;
Sampling of amniotic fluid in case of cesarean section&#xD;
Sampling of the placenta for histological and virological study.</description>
    <arm_group_label>mothers infected with SARS-COV-2 at the time of delivery.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples concern newborns of SARS-COV-2 + mothers at birth</intervention_name>
    <description>In the birth room:&#xD;
Collection of gastric fluid (PCR SARS-COV-2),&#xD;
Cord blood: 1 EDTA tube (immunohistochemistry), 1 yellow tube (SARS-COV-2 + RT-qPCR serology).&#xD;
In the newborn at D3 of life:&#xD;
- 1 yellow tube (SARS-COV-2 + RT-qPCR serology) at the same time as the DNN.&#xD;
In symptomatic newborns:&#xD;
1 yellow tube (SARS-COV-2 + RT-qPCR serology).&#xD;
nasopharyngeal PCR,</description>
    <arm_group_label>mothers infected with SARS-COV-2 at the time of delivery.</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PCR nasopharyngeal, blood (serology SARS-COV-2 and RT-qPCR), placental tissues (see details)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant woman with proven SARS-COV-2 infection during full-term delivery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Social security affiliation&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Pregnant woman with proven SARS-COV-2 infection during full-term delivery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient vaccinated within 15 days prior to inclusion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugues PATURAL, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hugues PATURAL, PhD</last_name>
    <phone>(0)477828542</phone>
    <phone_ext>+33</phone_ext>
    <email>Hugues.patural@chu-st-etienne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-Ã‰tienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>HUGUES PATURAL, PhD</last_name>
      <phone>(0)477828542</phone>
      <phone_ext>+33</phone_ext>
      <email>Hugues.patural@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Kareen BILLIEMAZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tiphaine BARJAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie PILLET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isaure THIBAUDIN, INTERN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immune response</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>ACE2 receptors</keyword>
  <keyword>MPRSS2</keyword>
  <keyword>cathepsin L</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

